MEDIA RELEASE
FOR IMMEDIATE RELEASE

13 March 2018

TREATING LIVER FAILURE WITH STEM CELL-DERIVED LIVER CELLS IN THE FUTURE

Singapore – A research collaboration between A*STAR’s Genome Institute of Singapore (GIS) and Institute of Molecular and Cellular Biology (IMCB), and the Stanford University School of Medicine, has discovered methods to efficiently generate pure liver cells from human stem cells. This could lead to more effective ways of treating liver failure.

The team, led by Dr Ang Lay Teng and Dr Bing Lim from GIS, Professor Kyle Loh and Professor Irving Weissman from the Stanford University School of Medicine, and Dr Chen Qingfeng from IMCB, also successfully grafted the generated liver cells into mouse models which improved their short-term survival rate.

Liver disease has few treatments and imposes a substantial healthcare and economic burden. Currently, end-stage liver failure can only be treated by liver transplants. Due to the scarce supply of liver donations, more than one million patients worldwide die every year while waiting for transplants. To address this problem, the researchers aim to artificially generate large numbers of liver cells from human embryonic stem cells.

“Embryonic stem cells have the potential to turn into thousands of cell-types in the human body. The key is to understand how to turn them solely into liver cells. Generating these highly-pure liver cells from embryonic stem cells is an important step towards using these cells for cell transplantation,” said Dr Ang Lay Teng, Senior Research Fellow at GIS. She explained, “The process of generating highly-pure liver cells involves a series of steps. As the whole process of liver development is not fully clear, one major challenge we faced was how to precisely control the development of stem cells into liver cells.”

“With almost unlimited development potential, embryonic stem cells can be made to develop into any other cell. The stem cell’s development is similar to a complex train map. In this case, the generation of liver cells would be our destination. The crux of our research is to identify the six requisite stops and map the path needed for a stem cell to develop into a liver cell,” added Professor Kyle Loh, Assistant Professor at the Stanford University School of Medicine.

Dr Ang continued, “Another major challenge was the difficulty in obtaining liver cells which were derived from human embryonic stem cells. These cells also needed to be capable of regenerating real liver tissue in animal models. However, our stem cell-derived liver cells were able to be successfully grafted into mouse models with liver

injuries. This process improved their short-term survival remarkably. With progress, there is potential to eventually treat patients with liver failure in the future.”

Dr Ng Huck Hui, Executive Director of GIS, said, “The ability to generate large quantities of stem-cell derived liver cells holds the potential to sustain patients with liver failure while they await a full liver transplant. This holds great promise for helping to improve patient survival rates and alleviate the burden of liver failure on societies.”

The research results were published in Cell Reports on 20 February 2018.

Images

(Copyright: A*STAR’s Genome Institute of Singapore)

Stem cell-derived liver cells.
Notes to Editor:

Lay Teng Ang¹,¹²,* Antson Kiat Yee Tan¹,¹⁰, Matias I. Autio²,³,¹⁰, Su Hua Goh¹, Siew Hua Choo¹, Kian Leong Lee⁴, Jianmin Tan¹, Bangfen Pan²,³, Jane Jia Hui Lee¹,⁵, Jen Jen Lum¹,⁶, Christina Ying Yan Lim¹, Isabelle Kai Xin Yeo¹,⁶, Chloe Jin Yee Wong¹,⁶, Min Liu⁸, Juween Ling Li Oh¹,⁶, Cheryl Pei Lynn Chia¹,⁶, Chet Hong Loh¹, Angela Chen⁷, Qingfeng Chen⁸,⁹, Irving L. Weissman⁷, Kyle M. Loh⁷,¹¹ and Bing Lim¹,¹¹,*

1. Stem Cell & Regenerative Biology Group, Genome Institute of Singapore, A*STAR, Singapore 138672, Singapore
2. Human Genetics Group, Genome Institute of Singapore, A*STAR, Singapore 138672, Singapore
3. Cardiovascular Research Institute, National University of Singapore, Singapore 117599, Singapore
4. Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore 169857, Singapore
5. School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore
6. School of Engineering, Temasek Polytechnic, Singapore 529757, Singapore
7. Stanford Institute for Stem Cell Biology & Regenerative Medicine, Department of Developmental Biology, Stanford-UC Berkeley Siebel Stem Cell Institute, Stanford University School of Medicine, Stanford, CA 94305, USA
8. Humanized Mouse Unit, Institute of Molecular and Cell Biology, A*STAR, Singapore 138673, Singapore
9. Department of Microbiology, Yong Yoo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore
10. These authors contributed equally
11. Senior author
12. Lead Contact

*/¹¹ Correspondence: anglt1@gis.a-star.edu.sg; limb1@gis.a-star.edu.sg.

For media queries and clarifications, please contact:

Lyn Lai
Officer, Office of Corporate Communications
Genome Institute of Singapore, A*STAR
Tel: +65 6808 8258
HP: +65 8742 3780
Email: lai_yilin@gis.a-star.edu.sg

About A*STAR’s Genome Institute of Singapore (GIS)
The Genome Institute of Singapore (GIS) is an institute of the Agency for Science, Technology and Research (A*STAR). It has a global vision that seeks to use genomic sciences to achieve extraordinary improvements in human health and public prosperity. Established in 2000 as a centre for genomic discovery, the GIS will pursue the integration of technology, genetics and biology towards academic, economic and societal impact.

The key research areas at the GIS include Human Genetics, Infectious Diseases, Cancer Therapeutics and Stratified Oncology, Stem Cell and Regenerative Biology, Cancer Stem Cell Biology, Computational and Systems Biology, and Translational Research.

The genomics infrastructure at the GIS is utilised to train new scientific talent, to function as a bridge for academic and industrial research, and to explore scientific questions of high impact.

For more information about GIS, please visit www.gis.a-star.edu.sg

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore’s lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society.

As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability.

We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and Research Institutes, the wider research community and industry. A*STAR oversees 18 biomedical sciences and physical sciences and engineering research entities primarily located in Biopolis and Fusionopolis.

For more information on A*STAR, please visit www.a-star.edu.sg.